Enhanced exercise-induced hyperkalemia in patients with syndrome X  by Bøtker, Hans Erik et al.
Syndrome X
Enhanced Exercise-Induced
Hyperkalemia in Patients With Syndrome X
Hans Erik Bøtker, MD, PHD,* Helle Sauer Sonne, MD,* Ole Frøbert, MD, PHD,*
Frederik Andreasen, MD, PHD†
Aarhus, Denmark
OBJECTIVES The purpose of this study was to determine whether patients with syndrome X have altered
potassium metabolism.
BACKGROUND Patients with syndrome X have angina pectoris and exercise induced ST segment depression
on the electrocardiogram despite normal coronary angiograms. Increasing evidence suggests
that myocardial ischemia is uncommon in these patients. Altered potassium metabolism
causing interstitial potassium accumulation in the myocardium may be an alternative
mechanism for chest pain and ST segment depression in syndrome X.
METHODS We compared the magnitude of exercise-induced hyperkalemia in 16 patients with syndrome
X (12 female and four male, mean 6 SD age 53 6 6 years) and 15 matched healthy control
subjects. The participants underwent a bicycle test at a fixed load of 75 W for 10 min, and
blood samples were taken for analysis of potassium, catecholamines and lactate before, during
and in the recovery period after exercise. In five patients with syndrome X, the test was
repeated during alpha1 adrenoceptor blockade.
RESULTS Baseline concentrations of serum potassium, plasma catecholamines and plasma lactate were
similar in patients and control subjects. The rate of exercise-induced increment of serum
potassium was increased in the patients (70 6 29 vs. 30 6 21 mmol/liter/min in control
subjects, p , 0.001). Six patients, who stopped before 10 min of exercise, showed very rapid
increments in serum potassium concentration. Compared to the control subjects, patients also
demonstrated larger increments in rate–pressure product, plasma norepinephrine and lactate
concentrations during exercise. The rate of serum potassium increment correlated with the
rate of plasma norepinephrine increment in the patients (r 5 0.63, p , 0.02), but not in the
control subjects (r 5 0.01, p 5 0.97). Blockade of alpha1 adrenoceptors decreased systolic
blood pressure at baseline, but did not influence the increment of serum potassium, plasma
catecholamines and lactate.
CONCLUSIONS Patients with syndrome X have enhanced exercise induced hyperkalemia in parallel with
augmented increases of circulating norepinephrine and lactate. The prevailing mechanisms
behind the abnormal potassium handling comprise sources distinct from alpha1-adrenoceptor
activation. (J Am Coll Cardiol 1999;33:1056–61) © 1999 by the American College of
Cardiology
The cardiologic syndrome X is characterized by angina
pectoris and ST segment depression during exercise testing
but normal coronary arteries at angiography. Increasing
evidence suggests that myocardial ischemia is uncommon in
these patients (1,2). It has been proposed that potassium
metabolism is altered in patients with syndrome X (3).
Potassium is released from the human myocardium under
conditions of stress or increases of heart rate (4). On
cessation of tachycardia the small net loss of intracellular
potassium is replaced to maintain a steady state. If patients
with syndrome X release a greater amount of intracellular
potassium or take up potassium more slowly, then potas-
sium could be retained in the myocardium. Such an accu-
mulation would account for features of syndrome X, includ-
ing chest pain, ST segment changes, modification of
coronary (5) and systemic vasoreactivity (6) and a good
prognosis (7). However, no confirmatory data exist to
support this hypothesis. Potassium regulation during exer-
cise may reflect disturbances of potassium metabolism,
because patients with syndrome X in addition to angina
pectoris often suffer from generalized fatigue in the skeletal
muscles (8). To determine whether there is any evidence of
a disturbed potassium metabolism in patients with syn-
drome X we compared exercise-induced hyperkalemia in
patients with syndrome X and matched healthy control
subjects.
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METHODS
Subjects. We studied 16 patients with syndrome X (typical
effort angina, $0.1 mV ST segment depression on bicycle
exercise testing and normal coronary angiograms) (Table 1).
Mean duration of symptoms was 4.2 years (range 6 months
to 12 years). All patients were otherwise healthy, and none
had concomitant cardiovascular or metabolic disease. Epi-
cardial spasm was excluded by a hyperventilation test.
Valvular and myocardial diseases were excluded by echocar-
diography and ventriculography. Ejection fraction was
.55% in all patients. Prior to the study 12 patients were
treated with calcium channel blocking agents, three with
beta-adrenergic blocking agents and 16 with long-acting
nitroglycerin.
Healthy control subjects were recruited among the hos-
pital staff and blood donors. They were matched to the
patients for age, gender, body mass index, maximal oxygen
uptake and blood pressure. None of the volunteers had a
history of neurologic, endocrinologic or cardiologic diseases.
All were free of medication, and had a normal clinical
investigation and a normal exercise electrocardiogram
(ECG).
Study design. The study was approved by the local Ethics
Committee. All medications were discontinued two weeks
before the study. Short-acting nitrates, however, were al-
lowed up to 6 h before the study. Investigations were
performed on two separate days within one week. At the
first visit, participants underwent exercise ECG testing.
Maximal aerobic capacity was expressed as peak oxygen
uptake (VO2 peak) (9). During a separate visit, the partici-
pants underwent a bicycle test at a fixed load of 75 W for
10 min. A computer-connected Schiller ERGOMETRIC
900 bicycle ergometer and a Schiller Cardiovit CS-6/12
Exec mingograph (Geneva, Switzerland) were used. Blood
pressure was measured automatically by a BOSCH EBM
blood pressure measure unit (Berlin, Germany) connected
to the computer. On the basis of the caloric coefficient of
oxygen uptake of 13.95 ml/min per watt (10), individual
oxygen uptake was extrapolated from workload as:
VO2(ml/kg/min) 5 W 3 13.95/body weight 1 3.5
where W is the workload obtained and 3.5 resting oxygen
consumption in ml/kg/min (11). A short catheter was
inserted into a large antecubital vein. The system was kept
patent by slow infusion of isotonic saline. Serum potassium
and albumin were measured at baseline, every 2.5 min
during the exercise test and at 1, 2, 3, 5, 7 and 10 min after
cessation of the bicycle test. Plasma epinephrine, plasma
norepinephrine and plasma lactate were measured before
and at the end of exercise. Analysis for serum potassium was
done with a standard method on a Kodak Ektachem 700
XR analyzer (Rochester, New York). For determination of
epinephrine and norepinephrine 4 ml of blood was collected
into glass tubes containing 80 ml ethylene glycol tetraacetic
acid (EGTA)/gluthation (76 mg EGTA and 6 mg gluta-
thion in 1 ml water, pH adjusted at 7.3). Samples were
centrifuged and stored at 280°C until analysis. Analyses
were performed using high performance liquid chromatog-
raphy (12). Blood samples for determination of lactate were
collected into heparinized ice-cooled glass tubes, centri-
fuged, deproteinized and stored at 280°C until later dupli-
cate analysis. Plasma lactate was determined enzymatically
using lactate dehydrogenase at pH 5 9.0 (13).
The study was repeated in five patients after administra-
tion of an alpha1 adrenoceptor antagonist, doxazosin (Car-
duran) 2 mg orally 2 h before the test.
Statistical methods. Data are presented as mean 6 SD.
Mean values are compared using paired and unpaired t tests.
Correlations are assessed by linear regression analysis. A p
value ,0.05 is considered statistically significant.
RESULTS
Baseline serum potassium, plasma lactate, epinephrine and
norepinephrine concentrations were similar in patients and
control subjects (Table 2). Six patients with syndrome X
terminated exercise testing before 10 min of exercise due to
anginal pain. The individual increases of serum potassium
Abbreviations and Acronyms
ATPase 5 adenosine triphosphatase
ECG 5 electrocardiogram
EGTA 5 ethylene glycol tetraacetic acid
VO2 peak 5 peak oxygen uptake
Table 1. Characteristics of Participants
Controls
(n 5 15)
Syndrome X
(n 5 16)
Clinical data
Gender (male/female) 3/12 4/12
Age (yr) 53 6 7 56 6 6
Body mass index 24.4 6 2.6 23.2 6 3.0
Smokers/nonsmokers 5/10 7/9
Blood pressure
Systolic 126 6 14 123 6 15
Diastolic 83 6 9 78 6 10
Serum lipids
Cholesterol (mmol/liter) 5.5 6 1.2 6.1 6 1.1
HDL cholesterol (mmol/liter) 1.56 6 0.30 1.57 6 0.48
Triglycerides (mmol/liter) 1.16 6 0.41 1.45 6 0.83
Baseline exercise test
Maximal ST segment depression
(mV)
0 0.15 6 0.05
Rate–pressure product ([mm Hg 3
beat per minute] 3 102)
328 6 36 294 6 52
Peak O2 uptake (ml/kg/min) 31.1 6 6.6 27.2 6 5.3
Data are mean 6 SD.
HDL 5 high density lipoprotein.
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during exercise in these patients are depicted in Figure 1,
which also shows that the exercise-induced hyperkalemia is
enhanced in the remaining syndrome X patients compared
to the control subjects.
Absolute values of VO2 during exercise did not differ
between patients and control subjects (18.7 6 2.0 and
20.1 6 2.6 ml/kg/min, p 5 0.11). However, the relative
value of the actual VO2 during the fixed workload in
percentage of VO2 peak was significantly higher in the pa-
tients than in the control subjects (76 6 14% vs. 63 6 16%,
p , 0.05). Correction for variations in relative submaximal
effort by calculating the ratio of [rate of serum potassium
increment/VO2 during fixed workload in proportion to
VO2 peak] showed that the difference in the rate of serum
potassium increment between patients and control subjects
persisted (91 6 27 vs. 51 6 34 mmol/liter/min, p , 0.001).
During exercise, patients with syndrome X revealed larger
increments in rate–pressure product, plasma norepinephrine
and lactate concentrations than control subjects (Table 2).
Four patients had ST segment depressions $0.1 mV at the
termination of exercise. Among these one patient stopped
exercise after 5 min and 10 s, whereas the remaining three
patients completed the 10-min exercise scheme. No signif-
icant correlations were observed between the rate of potas-
sium increment and rate of lactate increment in patients
(r 5 0.42, p 5 0.11) or control subjects (r 5 0.08, p 5
0.77). In the patient group, the rate of potassium increment
correlated with the rate of norepinephrine increment (r 5
0.63, p , 0.02), whereas no correlation was found in control
subjects (r 5 0.01, p 5 0.97). In the recovery period, the
rate of serum potassium decrease did not differ between
patients and control subjects (31 6 19 and 38 6 20
mmol/liter/min, p 5 0.30).
After doxazosin administration to five of the patients who
completed 10 min of bicycling during the first test, systolic
blood pressure at baseline was decreased compared to the
test without doxazosin (Table 3). Baseline plasma concen-
trations of potassium, epinephrine, norepinephrine and
lactate were unchanged after doxazosin. During exercise the
increase in rate–pressure product was unchanged with dox-
azosin, whereas the increases of plasma catecholamines
tended to be higher after doxazosin administration. The
increases in potassium and lactate were similar with and
without doxazosin.
DISCUSSION
The present study shows that patients with syndrome X
exhibit enhanced exercise-induced hyperkalemia in parallel
with augmented increases of circulating norepinephrine and
lactate concentrations compared to a matched group of
healthy control subjects. The enhanced exercise-induced
Table 2. Baseline Data and Exercise Responses of Rate–Pressure
Product, Serum-Potassium, Plasma Epinephrine, Plasma
Norepinephrine and Plasma Lactate in Control Subjects and
Patients With Syndrome X
Controls
(n 5 15)
Syndrome X
(n 5 16) p
Baseline data
Serum potassium
(mmol/liter)
3.96 6 0.24 3.77 6 0.20 0.08
Plasma epinephrine
(pg/ml)
62 6 38 45 6 25 0.37
Plasma norepinephrine
(pg/ml)
441 6 243 595 6 326 0.14
Plasma lactate
(mmol/liter)
0.88 6 0.24 0.79 6 0.29 0.57
Exercise data
Increase in
rate–pressure
product
([mm Hg 3 beats/
min] 3 102)
8,942 6 2,987 13,959 6 4,604 ,0.01
Serum potassium
increment
(mmol/liter)
0.31 6 0.22 0.56 6 0.17 ,0.02
Plasma epinephrine
increment (pg/ml)
38 6 81 33 6 31 0.98
Plasma norepinephrine
increment (pg/ml)
395 6 305 940 6 708 ,0.02
Plasma lactate
increment
(mmol/liter)
1.33 6 1.23 3.01 6 1.55 ,0.01
Rate of serum
potassium increment
(mmol/liter/min)
30 6 21 70 6 29 ,0.001
Figure 1. Changes in plasma potassium concentration (means 6
SD) during exercise and in the recovery period after exercise in 10
patients with syndrome X (solid circles) and 16 matched control
subjects (open circles). Changes in six patients who stopped before
10 min of exercise are shown individually (triangles). *p , 0.05
versus control subjects.
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hyperkalemia in patients with syndrome X is not modulated
by the alpha1 adrenergic antagonist doxazosin.
Potassium regulation. Acute potassium homeostasis is
controlled by extrarenal tissues and determined by epineph-
rine, norepinephrine and insulin (14). The abnormal potas-
sium handling in patients with syndrome X is thought to
affect the transport of potassium between intracellular and
extracellular myocardial compartments and therefore in-
volves components responsible for the acute regulation of
potassium balance (15). Assessment of myocardial potas-
sium exchange by determination of potassium concentra-
tions in the coronary sinus is suboptimal because the
measured changes may be small (2).
The skeletal muscles contain the largest pool of potas-
sium in the body (75% of total) (14). The regulatory
mechanisms of transsarcolemmal exchange of potassium in
skeletal muscle and cardiac muscle are similar and appear to
involve identical structures (16). Thus, we chose to study the
acute regulation of potassium metabolism during exercise.
We used a moderate workload (on average 70% of peak
VO2) for a limited duration because it represents an integral
part of the lifestyle in many adults and produces a predict-
able yet modest increase in the serum potassium concentra-
tion (17). We used the same absolute workload in all
participants because the peak concentrations of potassium in
plasma during exercise are proportional to exercise intensity,
contracting muscle mass and the level of physical capacity
(18,19). Syndrome X patients are expected to have compro-
mised physical capacity because exercise induces angina
pectoris. Thus, we sought to eliminate these confounders by
selecting the control group to match the patient group as
closely as possible with respect to body mass index and
VO2 peak. Even so, the relative value of VO2 during the fixed
workload in percentage of VO2 peak was, on average, higher
in the patients than in the control subjects. These findings
suggest that this workload is closer to the anaerobic thresh-
old in the patients than in the control subjects (20), so that
the enhanced hyperkalemia during exercise may be associ-
ated with a reduction of aerobic capacity. However, ratios
for rate of potassium increments/VO2 during fixed workload
in percentage of VO2 peak showed that the difference in
exercise-induced hyperkalemia persisted after correction for
individual variations in relative submaximal effort.
Exercise, catecholamines and insulin. The main cellular
mechanism regulating exercise-induced hyperkalemia is the
Na1,K1, adenosine triphosphatase (ATPase) in skeletal
muscle (14). The concentration of Na1,K1,ATPase exceeds
the demands for Na1–K1 transport under usual physiologic
conditions (14), and it is generally accepted that increased
activation of the Na1,K1,ATPase is responsible for the
reduction of exercise-induced hyperkalemia. Catecholamines
increase K1 influx and Na1 efflux through selective beta2
adrenoceptor stimulation (17). Several studies have indi-
cated that sympathetic activity in patients with syndrome X
is increased (21–23). The results of the present study show
that the enhanced exercise-induced hyperkalemia in pa-
tients with syndrome X occurs despite a simultaneously
augmented increase in plasma norepinephrine. Moreover,
the increase in norepinephrine and the increase in potassium
correlated in the patients. This observation, together with
previous observations that alpha-adrenergic stimulation
causes an elevation of plasma potassium concentration
(24,25), which can be reversed by phentolamine, an alpha-
receptor antagonist, prompted us to study the influence of
doxazosin, a selective alpha1 adrenoceptor antagonist, on
exercise-induced hyperkalemia. Doxazosin increases the
coronary flow reserve in patients with syndrome X (26).
Assessed by the significant hemodynamic effect of doxazosin
Table 3. Baseline Data and Exercise Responses of Rate–Pressure Product, Serum Potassium,
Plasma Epinephrine, Plasma Norepinephrine and Plasma Lactate in Five Patients With
Syndrome X Before and After Doxazosin Administration
Before
doxazosin
After
doxazosin p
Baseline data
Mean blood pressure (mm Hg) 94 6 13 88 6 11 ,0.01
Serum potassium (mmol/liter) 3.87 6 0.10 3.94 6 0.11 0.41
Plasma epinephrine (pg/ml) 36 6 18 44 6 32 0.35
Plasma norepinephrine (pg/ml) 424 6 159 405 6 61 0.40
Plasma lactate (mmol/liter) 0.55 6 0.06 0.87 6 0.36 0.06
Exercise data
Increase in rate–pressure product ([mm
Hg 3 beat per minute] 3 1022)
16,376 6 4,579 16,934 6 5,726 0.37
Serum potassium increment (mmol/liter) 0.68 6 0.08 0.62 6 0.33 0.31
Plasma epinephrine increment (pg/ml) 23 6 20 72 6 98 0.13
Plasma norepinephrine increment (pg/ml) 769 6 480 1,278 6 1,085 0.08
Plasma lactate increment (mmol/liter) 2.85 6 1.05 2.63 6 2.56 0.39
Rate of serum potassium increment
(mmol/liter/min)
68 6 8 62 6 33 0.31
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at rest, we achieved sufficient alpha1 blockade, but the
hyperkalemic response during exercise was not modified.
This finding tends to exclude a significant involvement of
alpha1 adrenoceptor activation in the enhanced exercise-
induced hyperkalemia in patients with syndrome X. At
present, it is unknown whether the effect of alpha-
adrenergic modification of potassium homeostasis is medi-
ated via the alpha1 or alpha2 receptor. Because unspecific
alpha-adrenoceptor blockade with phentolamine diminishes
the exercise-induced rise in plasma potassium concentration
in healthy subjects (27), we cannot exclude the possibility
that an effect is mediated through the alpha2 receptor.
Insulin reduces the circulating potassium concentration
by stimulation of the Na1,K1,ATPase in skeletal muscle.
Patients with syndrome X are characterized by impaired
insulin-stimulated glucose uptake in skeletal and cardiac
muscle (28), but the actions of insulin on cellular glucose
and potassium uptake are independent of one another
(29,30). We have recently demonstrated that potassium
handling in response to insulin is similar in patients with
syndrome X and control subjects (28). Thus, insulin is not
likely to be involved in the abnormal potassium handling
during exercise in patients with syndrome X.
Limitations. Although high extracellular concentrations of
potassium are associated with ST segment depressions
similar to those observed in the present study during
exercise, the maximal serum potassium concentrations ob-
served here were far from the serum concentrations of 8 to
12 mmol/liter that cause ST segment depression (31).
However, the use of a catheter in the cubital vein may be a
relatively insensitive way to characterize myocardial potas-
sium delivery compared with arterial or arteriovenous blood
sampling over a specified group of exercising skeletal mus-
cles, for example, in the leg. Since the exercise in the present
study was carried out on a bicycle, only a minor part of the
work was done by the arm muscles. Thus, the arm muscles
may extract rather than release potassium so that the
concentration in the cubital vein may be underestimated
compared with the central vessels.
Conclusions and implications. So far, we have demon-
strated that potassium metabolism during exercise is altered
in patients with syndrome X. These findings may account
for the high prevalence of generalized fatigue in the skeletal
muscles (8), because excessive potassium efflux from skeletal
muscle reduces the potassium gradient between the intra-
and extracellular compartments and impairs action potential
transmission and consequently tension development (32).
Potassium acts as a mediator of cardiac pain per se (33,34)
and in combination with other chemical mediators such as
adenosine (35). Whether the abnormal potassium handling
in patients with syndrome X also involves cardiac muscle,
causing localized interstitial hyperkalemia, cannot be deter-
mined from the present study. In the absence of any
demonstrable perfusion abnormality, the uptake and wash-
out of the potassium analog thallium-201 is reduced in
patients with syndrome X (36). This may be a result of
abnormal myocardial potassium handling.
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